Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
45 participants
INTERVENTIONAL
2022-12-17
2026-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Medical Device to Treat Brain Aneurysms
NCT04963933
An EFS Assessing the Electrolytic eCLIPs System for Treatment of Intracranial Aneurysms
NCT04886505
Reverse Medical Barrel™ Device for Adjunctive Treatment for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms
NCT02179190
Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device
NCT02186561
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm
NCT06411418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with the device
Nautilus Intrasaccular Bridging System
Patients will be treated with the Nautilus, then followed-up for 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nautilus Intrasaccular Bridging System
Patients will be treated with the Nautilus, then followed-up for 12 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject who presents with an angiographically confirmed, wide neck intracranial saccular, acutely ruptured aneurysm. Wide neck is defined as 4-7mm.
3. Aneurysm dome ≥5 mm.
4. Subject is neurologically stable with a Hunt \& Hess score of I, II, or III.
5. In the opinion of the treating physician, placement of the Nautilus is technically feasible and clinically reasonable.
6. The subject or authorized representative is able to provide informed consent and has signed the IRB-approved informed consent form.
7. Subject must be able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.
Exclusion Criteria
2. Premorbid mRS score ≥3.
3. Subject has another aneurysm which, in the Investigator's opinion, will require treatment within the follow-up period (1 year).
4. Women of child-bearing potential age (18-55) who cannot provide a negative pregnancy test.
5. Subject with other serious comorbidities that carry a high risk of neurologic events such as:
* Significant acute or chronic cardiovascular disease such as myocardial infarction within the past 180 days
* Uncorrectable coagulation abnormality
* Uncontrolled diabetes mellitus with target organ injury
* Organ failure of kidney, liver, heart or lungs
* Arteriovenous malformation or arteriovenous fistula, Moyamoya disease, or any other vasoconstriction
* Premorbid intracranial tumor or hematoma
6. Severe or unstable conditions or diseases (e.g., non-significant neurological deficit, cancer, hematologic or coronary disease) or chronic conditions that in the opinion of the investigator may increase the risk associated with study participation for study device administration or may interfere with the interpretation of study results.
7. Extreme vessel stenosis or tortuosity or other vascular anomalies that would prevent delivery of the device to the target.
8. Comorbidities that may preclude obtaining follow-up DSA.
9. Known allergy to Nickel and/or Heparin that cannot be medically treated.
10. Subject is currently participating in another interventional clinical study.
11. Subject with a relative contraindication to angiography (i.e., allergy to contrast media, coagulopathy, etc.)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EndoStream Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baptist Health Ambulatory Services, Inc. d/b/a/ Baptist Health Research Institute
Jacksonville, Florida, United States
University of South Florida
Tampa, Florida, United States
The research Foundation For The State Of New York On Behalf Of The University At Buffalo
Buffalo, New York, United States
Mount Sinai
New York, New York, United States
UMHAT "Sv. Ivan Rilski" EAD
Sofia, Sofia, Bulgaria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLD-329(US)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.